Lilly Boosts Investment in Chinese Firm

Eli Lilly & Co. increased its investment in China generic-drug maker Novast Laboratories Ltd. by $20 million and expanded their collaboration to enhance Lilly’s efforts to offer branded generic medicines in the country.
The Wall Street Journal